Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results

es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus trastuzumab plus capecitabine
tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine 2 noneinconclusive results for: AE leading to treatment discontinuation (any grade)

statistically conclusive 34 % decrease in deaths (OS) but the degree if certainty is unassessable

statistically conclusive 46 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable

-